Icosavax (ICVX) Stock Price, News & Analysis

Company Overview

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.

Key Stats

• Today's Range: $15.31 to $15.31
• 50-Day Range: $15.31 to $15.45
• 52-Week Range: $4.75 to $16.10
• Volume: N/A
• Average Volume: 1.22 million shs
• Market Capitalization: $766.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $26.50
• Consensus Rating: Hold

Icosavax Stock Analysis - MarketRank™

Icosavax scored higher than 30% of companies evaluated by MarketBeat, and ranked 828th out of 995 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Icosavax has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Icosavax has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Icosavax are expected to decrease in the coming year, from ($2.20) to ($2.21) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Icosavax is -6.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Icosavax is -6.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Icosavax has a P/B Ratio of 2.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ICVX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Icosavax does not currently pay a dividend.

Dividend Growth

Icosavax does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for ICVX.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for ICVX on MarketBeat in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Icosavax insiders have not sold or bought any company stock.

Percentage Held by Insiders

30.59% of the stock of Icosavax is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

92.59% of the stock of Icosavax is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ICVX Stock Analysis - Frequently Asked Questions

How were Icosavax's earnings last quarter?

Icosavax, Inc. (NASDAQ:ICVX) posted its earnings results on Monday, November, 15th. The company reported ($1.30) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by $0.81. The firm earned $1.83 million during the quarter, compared to analyst estimates of $3.30 million.

When did Icosavax IPO?

Icosavax (ICVX) raised $150 million in an initial public offering (IPO) on Thursday, July 29th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share.

Company Calendar

• Last Earnings: 11/15/2021
• Today: 9/16/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ICVX
• CUSIP: N/A
• CIK: 1786255
• Web: icosavax.com
• Phone: 206-737-0085
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $26.50
• High Stock Price Target: $28.00
• Low Stock Price Target: $25.00
• Potential Upside/Downside: +73.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-91,760,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -43.06%
• Return on Assets: -39.53%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 18.06
• Quick Ratio: 18.06

Sales & Book Value

• Annual Sales: $580,000.00
• Price / Sales: 1,322.20
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.47 per share
• Price / Book: 2.80

Miscellaneous

• Outstanding Shares: 50,090,000
• Free Float: 34,767,000
• Market Cap: $766.88 million
• Optionable: Optionable
• Beta: 1.28